TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
paper
Cited
Public
- Authors
- Gregory, Adam P; Dendrou, Calliope A; Attfield, Kathrine E; Haghikia, Aiden; Xifara, Dionysia K; Butter, Falk; Poschmann, Gereon; Kaur, Gurman; Lambert, Lydia; Leach, Oliver A; Prömel, Simone; Punwani, Divya; Felce, James H; Davis, Simon J; Gold, Ralf; Nielsen, Finn C; Siegel, Richard M; Mann, Matthias; Bell, John I; McVean, Gil; Fugger, Lars
- Year
- 2012
- Journal
- Nature
- PMID
- 22801493
- DOI
- 10.1038/nature11307
- PMCID
- PMC4268493
Although there has been much success in identifying genetic variants associated with common diseases using genome-wide association studies (GWAS), it has been difficult to demonstrate which variants are causal and what role they have in disease. Moreover, the modest contribution that these variants make to disease risk has raised questions regarding their medical relevance. Here we have investigated a single nucleotide polymorphism (SNP) in the TNFRSF1A gene, that encodes tumour necrosis factor receptor 1 (TNFR1), which was discovered through GWAS to be associated with multiple sclerosis (MS), but not with other autoimmune conditions such as rheumatoid arthritis, psoriasis and Crohn’s disease. By analysing MS GWAS data in conjunction with the 1000 Genomes Project data we provide genetic evidence that strongly implicates this SNP, rs1800693, as the causal variant in the TNFRSF1A region. We further substantiate this through functional studies showing that the MS risk allele directs expression of a novel, soluble form of TNFR1 that can block TNF. Importantly, TNF-blocking drugs can promote onset or exacerbation of MS, but they have proven highly efficacious in the treatment of autoimmune diseases for which there is no association with rs1800693. This indicates that the clinical experience with these drugs parallels the disease association of rs1800693, and that the MS-associated TNFR1 variant mimics the effect of TNF-blocking drugs. Hence, our study demonstrates that clinical practice can be informed by comparing GWAS across common autoimmune diseases and by investigating the functional consequences of the disease-associated genetic variation.
MS-associated TNFRSF1A region and rs1800693-dependent splicing. (a) MS association signal plot for the UK cohort4. Top: primary association with strongest signal at rs1800693 (blue: typed variants; light blue: variants imputed from 1000 Genomes Project). Bottom: signal conditional on rs1800693 (red: typed; orange: imputed). Inset: linkage disequilibrium to rs1800693 in 1000 Genomes Project (black: typed; untyped - red: r2≥0.05; blue: r2<0.05). (b) Rs1800693-dependent TNFR1 splicing using a minigene system. SD/SA: vector splice donor/acceptor site. (c) Relative expression of transcripts lacking exon 6 in primary human cells. Data = mean ±SEM; for A/A, A/G, G/G, n = 15, 28 and 13 donors.
Δ6-TNFR1 localization and analysis of isoform association. (a) TNFR1 subcellular localization. (b) FL/Δ6-TNFR1 localization analysis. Data = mean ±SEM; FL-TNFR1, n = 20, Δ6-TNFR1, n = 27 cells; scale bar: 1 μm. (c) FL/Δ6-TNFR1 association analysis. HEK 293T double-positive cells expressing ECFP/EYFP-tagged TNFR1 isoforms were analyzed for FRET to assess isoform association. FL-TNFR1-ECFP + FAS180-EYFP co-transfection was used for background signal definition with non-interacting proteins. Percentage of FRET-positive events (indicating protein association) is shown. (d) HEK 293T cells expressing HA-tagged FL- or Δ6-TNFR1-EYFP were analyzed for cell surface and total protein expression. ECFP/EYFP: enhanced cyan/yellow fluorescent protein.
Δ6-TNFR1 solubility and TNF binding and neutralization. (a) Soluble TNFR1 detected by anti-HA ELISA using TNFR1-transfected HEK 293T supernatants. AFU: absolute fluorescence units; NT: non-transfected. (b) TNF-FLAG pulldown using TNFR1-Fc proteins. Inset: negative control for TNF binding (DR5.CRD1-Fc). (c) Surface plasmon resonance analysis of TNFR1-Fc protein TNF binding. Sensorgrams show resonance units (RU) over time and model fit for dissociation constant (Kd) derivation. (d) TNF neutralization by TNFR1-Fc proteins using HEK-Blue™ TNFα SEAP reporter cells. Dotted lines = IC50 for TNFR1-Fc and Δ6-TNFR1-Fc (158 and 3,035 ng/ml, respectively). Data = mean ±SEM; n = 3.
1–20 of 25
Next →
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation. | de la Rosa C et al. | — | 2026 | → |
| Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage. | Varra FN et al. | — | 2026 | → |
| Monophasic multifocal motor neuropathy with concomitant central nervous system demyelination following anti-TNFα therapy. | Zavarella M et al. | — | 2026 | → |
| Complementary Strategies to Identify Differentially Expressed Genes in the Choroid Plexus of Patients with Progressive Multiple Sclerosis. | Rodrigues ABM et al. | — | 2025 | → |
| Comprehensive Update on Multiple Sclerosis-Associated Uveitis and New Epidemiological Insights from the United Kingdom. | Heppell C et al. | — | 2025 | → |
| Genetically proxied tumour necrosis factor inhibition and pregnancy-related maternal and foetal outcomes in the general population: a Mendelian randomization study. | Zhao SS et al. | — | 2025 | → |
| Is DEXI a Multiple Sclerosis Susceptibility Gene? | Eriksson AM et al. | — | 2025 | → |
| Localization of Organelle Proteins Using Data-Independent Acquisition (DIA-LOP). | McCaskie K et al. | — | 2025 | → |
| Mast cells in autoimmune disease: Unveiling their multifaceted roles and therapeutic potential. | Javan MR et al. | — | 2025 | → |
| Molecular dynamics simulation of wild and mutant proteasome subunit beta type 8 (PSMB8) protein: Implications for restoration of inflammation in experimental autoimmune encephalomyelitis pathogenesis. | Paul SK et al. | — | 2025 | → |
| Pathways to Progressive Disability in Multiple Sclerosis: The Role of Glial Cells in Chronic CNS Inflammation. | Siffrin V | — | 2025 | → |
| RIPK1 signaling pathways: implications for autoimmune and neuroinflammatory diseases. | Pajulas A et al. | — | 2025 | → |
| Role of Tumor Necrosis Factor in Tuberculosis. | Kireev FD et al. | — | 2025 | → |
| Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity. | Naseer MA et al. | — | 2025 | → |
| The genomic architecture of circulating cytokine levels points to drug targets for immune-related diseases. | Konieczny MJ et al. | — | 2025 | → |
| The Polygenic Nature of Multiple Sclerosis: Genetic Variants, Immunological Modulation, and Environmental Connections. | Khan Z et al. | — | 2025 | → |
| The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases. | Khademi Z et al. | — | 2025 | → |
| Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis. | Wei J et al. | — | 2025 | → |
| Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases. | Bittner S et al. | — | 2025 | → |
| Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis. | Gomez-Pinedo U et al. | — | 2025 | → |
| A compendium of genetic variations associated with promoter usage across 49 human tissues. | Yuan J et al. | — | 2024 | → |
| Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. | Mateu-Arrom L et al. | — | 2024 | → |
| Examining the link between TNF inhibition and alopecia areata using Mendelian randomization. | Zhao SS | — | 2024 | → |
| Genetic mapping across autoimmune diseases reveals shared associations and mechanisms. | Lincoln MR et al. | — | 2024 | → |
| Genome‑wide association study and polygenic risk scores predict psoriasis and its shared phenotypes in Taiwan. | Yang JS et al. | — | 2024 | → |
| Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease [RETRACTED]. | — | — | 2024 | → |
| Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor-Inhibitor Treatment for Autoimmune Diseases: A Systematic Review and Meta-Analysis. | Xie W et al. | — | 2024 | → |
| Senescent response in inner annulus fibrosus cells in response to TNFα, H2O2, and TNFα-induced nucleus pulposus senescent secretome. | Montgomery-Song A et al. | — | 2024 | → |
| Signaling Pathways Concerning Mitochondrial Dysfunction: Implications in Neurodegeneration and Possible Molecular Targets. | Sharma Y et al. | — | 2024 | → |
| Targeting cytokine networks in neuroinflammatory diseases. | Becher B et al. | — | 2024 | → |
| The Role of Gut-derived Short-Chain Fatty Acids in Multiple Sclerosis. | Saadh MJ et al. | — | 2024 | → |
| Tumor necrosis factor mediates the impact of PM<sub>2.5</sub> on bone mineral density: Inflammatory proteome Mendelian randomization and colocalization analyses. | Li M et al. | — | 2024 | → |
| Common genetic factors among autoimmune diseases. | Harroud A et al. | — | 2023 | → |
| Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis. | Fiedler T et al. | — | 2023 | → |
| Genetic Basis of Inflammatory Demyelinating Diseases of the Central Nervous System: Multiple Sclerosis and Neuromyelitis Optica Spectrum. | Ortiz GG et al. | — | 2023 | → |
| Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. | Zhao JH et al. | — | 2023 | → |
| Impact of Tumor Necrosis Factor Receptor 1 (<i>TNFR1</i>) Polymorphism on Dry Eye Disease. | Acuna K et al. | — | 2023 | → |
| Inflammatory Cytokines Associated with Multiple Sclerosis Directly Induce Alterations of Neuronal Cytoarchitecture in Human Neurons. | Meyer-Arndt L et al. | — | 2023 | → |
| Inhibition of tumor necrosis factor receptor 1 and the risk of periodontitis. | Alayash Z et al. | — | 2023 | → |
| Mapping pQTLs of circulating inflammatory proteins identifies drivers of immune-related disease risk and novel therapeutic targets | The SCALLOP consortium et al. | — | 2023 | — |
| MIF Variant rs755622 Is Associated with Severe Crohn's Disease and Better Response to Anti-TNF Adalimumab Therapy. | Jezernik G et al. | — | 2023 | → |
| Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. | Gonzalez Caldito N | — | 2023 | → |
| Targeting RIPK1 kinase for modulating inflammation in human diseases. | Li W et al. | — | 2023 | → |
| The adaptation model of immunity: A new insight into aetiology and treatment of multiple sclerosis. | Manjili MH | — | 2023 | → |
| The Role of TNF-α in Alzheimer's Disease: A Narrative Review. | Plantone D et al. | — | 2023 | → |
| Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. | Konen FF et al. | — | 2023 | → |
| A case of Henoch-Schönlein purpura with underlying TRAPS (tumour necrosis factor receptor-associated periodic syndrome). | Jain K et al. | — | 2022 | → |
| A multiple sclerosis-protective coding variant reveals an essential role for HDAC7 in regulatory T cells. | Axisa PP et al. | — | 2022 | → |
| A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. | Sorosina M et al. | — | 2022 | → |
| Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. | Liu L et al. | — | 2022 | → |
| Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C. | Williams I et al. | — | 2022 | → |
| ATXN2-mediated translation of TNFR1 promotes esophageal squamous cell carcinoma via m<sup>6</sup>A-dependent manner. | Li R et al. | — | 2022 | → |
| Do amyloid fibrils induce inflammation, or does inflammation generate amyloid fibrils? | Rothbard JB | — | 2022 | → |
| Genetic overlap between type 1 diabetes and other autoimmune diseases. | Márquez A et al. | — | 2022 | → |
| Genetics and functional genomics of multiple sclerosis. | Kim W et al. | — | 2022 | → |
| Genetics of multiple sclerosis: lessons from polygenicity. | Goris A et al. | — | 2022 | → |
| Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. | Lee MH et al. | — | 2022 | → |
| Human Genomics and Drug Development. | Schmidt AF et al. | — | 2022 | → |
| Impact of Multiple Sclerosis Risk Polymorphism rs7665090 on MANBA Activity, Lysosomal Endocytosis, and Lymphocyte Activation. | González-Jiménez A et al. | — | 2022 | → |
| Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer. | Baram T et al. | — | 2022 | → |
| Mechanisms of action of anti-inflammatory proteins and peptides with anti-TNF-alpha activity and their effects on the intestinal barrier: A systematic review. | Lima MSR et al. | — | 2022 | → |
| Mendelian randomization study on the causal effects of tumor necrosis factor inhibition on coronary artery disease and ischemic stroke among the general population. | Kang X et al. | — | 2022 | → |
| Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis. | Chapman C et al. | — | 2022 | → |
| Splicing QTL analysis focusing on coding sequences reveals mechanisms for disease susceptibility loci. | Yamaguchi K et al. | — | 2022 | → |
| The immunology of multiple sclerosis. | Attfield KE et al. | — | 2022 | → |
| A catalog of GWAS fine-mapping efforts in autoimmune disease. | Caliskan M et al. | — | 2021 | → |
| A Missense Mutation rs781536408 (c.2395G>A) of <i>TYK2</i> Affects Splicing and Causes Skipping of Exon18 <i>in vivo</i>. | Chen S et al. | — | 2021 | → |
| Association of TNFRSF1A and IFNLR1 Gene Polymorphisms with the Risk of Developing Breast Cancer and Clinical Pathologic Features. | Hausmann LD et al. | — | 2021 | → |
| Can rheumatologists stop causing demyelinating disease? | Baker D et al. | — | 2021 | → |
| Defining the disease course of TNFα blockers-associated Multiple Sclerosis. | Lucchini M et al. | — | 2021 | → |
| Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review. | Barešić M et al. | — | 2021 | → |
| Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. | Taylor TRP et al. | — | 2021 | → |
| Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. | Yan Z et al. | — | 2021 | → |
| EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. | Nast A et al. | — | 2021 | → |
| Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKβ promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice. | Papazian I et al. | — | 2021 | → |
| Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel Multiple Sclerosis Risk Genes. | Li H et al. | — | 2021 | → |
| Genetic Variation on <i>TNF/LTA</i> and <i>TNFRSF1A</i> Genes is Associated with Outcomes of Hepatitis C Virus Infection. | Yue M et al. | — | 2021 | → |
| Host Genetics and Gut Microbiome: Perspectives for Multiple Sclerosis. | Maglione A et al. | — | 2021 | → |
| Insights into the biology and therapeutic implications of TNF and regulatory T cells. | Salomon BL | — | 2021 | → |
| Perspectives on the Genetic Associations of Ankylosing Spondylitis. | Wordsworth BP et al. | — | 2021 | → |
| Regulated cell death: discovery, features and implications for neurodegenerative diseases. | Cui J et al. | — | 2021 | → |
| The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. | Richter F et al. | — | 2021 | → |
| TNFR1-d2 carrying the p.(Thr79Met) pathogenic variant is a potential novel actor of TNFα/TNFR1 signalling regulation in the pathophysiology of TRAPS. | Rittore C et al. | — | 2021 | → |
| TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4<sup>+</sup>Foxp3<sup>+</sup> Regulatory T Cells: Implications in the Treatment of Autoimmune Diseases and Cancer. | Islam MS et al. | — | 2021 | → |
| Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. | Brummer T et al. | — | 2021 | → |
| Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study. | Kang X et al. | — | 2021 | → |
| A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. | Faergeman SL et al. | — | 2020 | → |
| Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. | Fugger L et al. | — | 2020 | → |
| Deciphering the heterogeneity of myeloid cells during neuroinflammation in the single-cell era. | Borst K et al. | — | 2020 | → |
| Distinct modes of TNF signaling through its two receptors in health and disease. | Atretkhany KN et al. | — | 2020 | → |
| Editorial: Pathophysiologic Insights From Biomarker Studies in Neurological Disorders. | Bittner S et al. | — | 2020 | → |
| Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand. | Vunnam N et al. | — | 2020 | → |
| Pathogenic T cell cytokines in multiple sclerosis. | Wagner CA et al. | — | 2020 | → |
| Post-mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms. | Fransen NL et al. | — | 2020 | → |
| PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders. | Engel S et al. | — | 2020 | → |
| Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. | Mifflin L et al. | — | 2020 | → |
| Re-Examining the Role of TNF in MS Pathogenesis and Therapy. | Fresegna D et al. | — | 2020 | → |
| Replication analysis of variants associated with multiple sclerosis risk. | Dashti M et al. | — | 2020 | → |
| Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. | Mechelli R et al. | — | 2020 | → |
| Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. | Kopp TI et al. | — | 2020 | → |
| Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. | Fischer R et al. | — | 2020 | → |
| The haplotypes of various TNF related genes associated with scleritis in Chinese Han. | Gao Y et al. | — | 2020 | → |
| Transcript specific regulation of expression influences susceptibility to multiple sclerosis. | Ban M et al. | — | 2020 | → |
| Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage. | Li Z et al. | — | 2020 | → |
| Aberrant expression of alternative splicing variants in multiple sclerosis - A systematic review. | Hecker M et al. | — | 2019 | → |
| Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. | Menegatti S et al. | — | 2019 | → |
| Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression. | Ewing E et al. | — | 2019 | → |
| Environmental and genetic risk factors for MS: an integrated review. | Waubant E et al. | — | 2019 | → |
| Genome analyses for the Tohoku Medical Megabank Project towards establishment of personalized healthcare. | Yasuda J et al. | — | 2019 | → |
| IL-22 Binding Protein Promotes the Disease Process in Multiple Sclerosis. | Lindahl H et al. | — | 2019 | → |
| Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates. | Paige E et al. | — | 2019 | → |
| Mitochondria in neuroinflammation - Multiple sclerosis (MS), leber hereditary optic neuropathy (LHON) and LHON-MS. | Bargiela D et al. | — | 2019 | → |
| Multiple sclerosis - a review. | Dobson R et al. | — | 2019 | → |
| Not only cancer: the long non-coding RNA MALAT1 affects the repertoire of alternatively spliced transcripts and circular RNAs in multiple sclerosis. | Cardamone G et al. | — | 2019 | → |
| [Pathological and protective effects of tumor necrosis factor-alpha in multiple sclerosis]. | Smagina IV et al. | — | 2019 | → |
| Post-stroke inflammation-target or tool for therapy? | Lambertsen KL et al. | — | 2019 | → |
| Targeting RIPK1 for the treatment of human diseases. | Degterev A et al. | — | 2019 | → |
| The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis. | Watts L et al. | — | 2019 | → |
| TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages. | Wajant H et al. | — | 2019 | → |
| TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells. | Raphael I et al. | — | 2019 | → |
| Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis. | Ribeiro CM et al. | — | 2019 | → |
| A New Venue of TNF Targeting. | Steeland S et al. | — | 2018 | → |
| Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. | Ristori G et al. | — | 2018 | → |
| Cytokines as Mediators of Neuroinflammation in Experimental Autoimmune Encephalomyelitis. | Gogoleva VS et al. | — | 2018 | → |
| Deciphering the Emerging Complexities of Molecular Mechanisms at GWAS Loci. | Cannon ME et al. | — | 2018 | → |
| Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. | Falcão AM et al. | — | 2018 | → |
| Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. | Bitoun S et al. | — | 2018 | → |
| Genetics of immune-mediated inflammatory diseases. | David T et al. | — | 2018 | → |
| Genetics of Multiple Sclerosis: An Overview and New Directions. | Patsopoulos NA | — | 2018 | → |
| Integrative functional genomics identifies regulatory genetic variant modulating RAB31 expression and altering susceptibility to breast cancer. | Zhang Y et al. | — | 2018 | → |
| Molecular and functional variation in iPSC-derived sensory neurons. | Schwartzentruber J et al. | — | 2018 | → |
| Multiple sclerosis genetics. | Canto E et al. | — | 2018 | → |
| [Nutrition, microbiome and multiple sclerosis : Current knowledge from basic research and clinical practice]. | Haghikia A et al. | — | 2018 | → |
| Role of innate immune system in the pathogenesis of ankylosing spondylitis. | Vanaki N et al. | — | 2018 | → |
| TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak population. | Javor J et al. | — | 2018 | → |
| Tumor Necrosis Factor Receptor Superfamily in T Cell Priming and Effector Function. | Muller J et al. | — | 2018 | → |
| Widespread intronic polyadenylation diversifies immune cell transcriptomes. | Singh I et al. | — | 2018 | → |
| 10 Years of GWAS Discovery: Biology, Function, and Translation. | Visscher PM et al. | — | 2017 | → |
| Alternative splicing regulation in tumor necrosis factor-mediated inflammation. | López-Urrutia E et al. | — | 2017 | → |
| Applications of the 1000 Genomes Project resources. | Zheng-Bradley X et al. | — | 2017 | → |
| CNS Demyelination with TNF-α Blockers. | Kemanetzoglou E et al. | — | 2017 | → |
| Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases. | Dreymueller D et al. | — | 2017 | → |
| Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. | Miquel-Serra L et al. | — | 2017 | → |
| Genetics in ankylosing spondylitis - Current state of the art and translation into clinical outcomes. | Brown MA et al. | — | 2017 | → |
| Immunomodulation in multiple sclerosis: promises and pitfalls. | Dendrou CA et al. | — | 2017 | → |
| Inflammation in the spotlight-clinical relevance of genetic variants affecting nuclear factor κB and tumor necrosis factor receptor 1. | Ortega FJ et al. | — | 2017 | → |
| Living in an adaptive world: Genomic dissection of the genus <i>Homo</i> and its immune response. | Quach H et al. | — | 2017 | → |
| Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140. | Mehta S et al. | — | 2017 | → |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | — | 2017 | → |
| The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. | Baranzini SE et al. | — | 2017 | → |
| The genetic underpinnings of body fat distribution. | Pulit SL et al. | — | 2017 | → |
| The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities. | Parnell GP et al. | — | 2017 | → |
| Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis. | Orthmann-Murphy JL et al. | — | 2017 | → |
| TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders. | Barreras P et al. | — | 2017 | → |
| TNFR1 inhibition with a Nanobody protects against EAE development in mice. | Steeland S et al. | — | 2017 | → |
| Acute Multiple Sclerosis Relapse. | Berkovich RR | — | 2016 | → |
| Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients. | Lomakin Y et al. | — | 2016 | → |
| A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. | Scott RA et al. | — | 2016 | → |
| An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation. | Roberts AR et al. | — | 2016 | → |
| Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. | Camp NJ et al. | — | 2016 | → |
| From genetic associations to functional studies in multiple sclerosis. | Bos SD et al. | — | 2016 | → |
| Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery. | Yarwood A et al. | — | 2016 | → |
| Induction of Colonic M Cells during Intestinal Inflammation. | Bennett KM et al. | — | 2016 | → |
| Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells. | Massa MG et al. | — | 2016 | → |
| Neuroinflammation - using big data to inform clinical practice. | Dendrou CA et al. | — | 2016 | → |
| Precision medicine of aneurysmal subarachnoid hemorrhage, vasospasm and delayed cerebral ischemia. | Burrell C et al. | — | 2016 | → |
| Reasoning over genetic variance information in cause-and-effect models of neurodegenerative diseases. | Naz M et al. | — | 2016 | → |
| Targeted genomic analysis reveals widespread autoimmune disease association with regulatory variants in the TNF superfamily cytokine signalling network. | Richard AC et al. | — | 2016 | → |
| Update on psoriasis immunopathogenesis and targeted immunotherapy. | Mahil SK et al. | — | 2016 | → |
| Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. | Robinson PC et al. | — | 2015 | → |
| An ImmunoChip study of multiple sclerosis risk in African Americans. | Isobe N et al. | — | 2015 | → |
| Anti-TNF therapy: past, present and future. | Monaco C et al. | — | 2015 | → |
| A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches. | Bashinskaya VV et al. | — | 2015 | → |
| Association of TNFAIP3 and TNFRSF1A variation with multiple sclerosis in a German case-control cohort. | Hoffjan S et al. | — | 2015 | → |
| Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. | Interleukin 1 Genetics Consortium | — | 2015 | → |
| Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. | Zandi MS et al. | — | 2015 | → |
| Combinations of susceptibility genes are associated with higher risk for multiple sclerosis and imply disease course specificity. | Akkad DA et al. | — | 2015 | → |
| Computational modeling of cytokine signaling in microglia. | Anderson WD et al. | — | 2015 | → |
| Genetic basis of autoimmunity. | Marson A et al. | — | 2015 | → |
| Genetic determinants of risk and progression in multiple sclerosis. | Didonna A et al. | — | 2015 | → |
| Genetic study of complex diseases in the post-GWAS era. | Huang Q | — | 2015 | → |
| Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. | Housley WJ et al. | — | 2015 | → |
| Genetic variation in PBMC-produced IFN-γ and TNF-α associations with relapse in multiple sclerosis. | Zhou Y et al. | — | 2015 | → |
| GWAS-identified multiple sclerosis risk loci involved in immune response: validation in Russians. | Bashinskaya VV et al. | — | 2015 | → |
| Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. | Cho JH et al. | — | 2015 | → |
| Immunopathology of multiple sclerosis. | Dendrou CA et al. | — | 2015 | → |
| Increased neutralization capacity of TNF-α in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-α receptors or anti-TNF-α autoantibody levels. | Mausner-Fainberg K et al. | — | 2015 | → |
| Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. | Haider L | — | 2015 | → |
| Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. | Fischer R et al. | — | 2015 | → |
| Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis. | van Luijn MM et al. | — | 2015 | → |
| Multiple sclerosis associated genetic variants of CD226 impair regulatory T cell function. | Piédavent-Salomon M et al. | — | 2015 | → |
| Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability. | Akkad DA et al. | — | 2015 | → |
| Neuroinflammatory TNFα Impairs Memory via Astrocyte Signaling. | Habbas S et al. | — | 2015 | → |
| Regulation of tumour necrosis factor signalling: live or let die. | Brenner D et al. | — | 2015 | → |
| Role of the innate and adaptive immune responses in the course of multiple sclerosis. | Hemmer B et al. | — | 2015 | → |
| Solving the puzzle of autoimmunity: critical questions. | Smilek DE et al. | — | 2015 | → |
| Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study. | Simpson S et al. | — | 2015 | → |
| Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. | Sankowski R et al. | — | 2015 | → |
| The autoimmune concept of multiple sclerosis. | Nicol B et al. | — | 2015 | → |
| The genomic landscape of human immune-mediated diseases. | Wu X et al. | — | 2015 | → |
| TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. | Probert L | — | 2015 | → |
| TNFR2 Deficiency Acts in Concert with Gut Microbiota To Precipitate Spontaneous Sex-Biased Central Nervous System Demyelinating Autoimmune Disease. | Miller PG et al. | — | 2015 | → |
| Translational utility of experimental autoimmune encephalomyelitis: recent developments. | Guerreiro-Cacais AO et al. | — | 2015 | → |
| Tumor necrosis factor stimulates expression of CXCL12 in astrocytes. | Blaževski J et al. | — | 2015 | → |
| A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function. | Stürner KH et al. | — | 2014 | → |
| Annotation of functional variation within non-MHC MS susceptibility loci through bioinformatics analysis. | Briggs FB et al. | — | 2014 | → |
| Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. | Williams SK et al. | — | 2014 | → |
| Approaches for establishing the function of regulatory genetic variants involved in disease. | Knight JC | — | 2014 | → |
| Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. | Martin RI et al. | — | 2014 | → |
| Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. | Winsauer C et al. | — | 2014 | → |
| Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. | Theibich A et al. | — | 2014 | → |
| Disease modification in multiple sclerosis: an update. | Rice CM | — | 2014 | → |
| Genetics of ankylosing spondylitis. | Robinson PC et al. | — | 2014 | → |
| Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. | Rittore C et al. | — | 2014 | → |
| Inflammatory bowel disease and demyelination: more than just a coincidence? | Katsanos AH et al. | — | 2014 | → |
| Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. | Fairfax BP et al. | — | 2014 | → |
| Laying a solid foundation for Manhattan--'setting the functional basis for the post-GWAS era'. | Zhang X et al. | — | 2014 | → |
| Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. | Fissolo N et al. | — | 2014 | → |
| Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. | Hartmann FJ et al. | — | 2014 | → |
| Multiple sclerosis genetics. | Sawcer S et al. | — | 2014 | → |
| Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. | Khan N et al. | — | 2014 | → |
| Myasthenia Gravis: paradox versus paradigm in autoimmunity. | Berrih-Aknin S | — | 2014 | → |
| Recent advances and future challenges in the genetics of multiple sclerosis. | Lill CM | — | 2014 | → |
| The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. | Robinson AP et al. | — | 2014 | → |
| The multiple sclerosis risk gene IL22RA2 contributes to a more severe murine autoimmune neuroinflammation. | Laaksonen H et al. | — | 2014 | → |
| Translational paradigms in pharmacology and drug discovery. | Mullane K et al. | — | 2014 | → |
| A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis. | Mechelli R et al. | — | 2013 | → |
| A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis. | Dendrou CA et al. | — | 2013 | → |
| Advances in blood pressure genomics. | Munroe PB et al. | — | 2013 | → |
| [Advances in the diagnosis, pathophysiology and treatment of chronic non-specific ulcerative colitis]. | González-Altamirano J et al. | — | 2013 | → |
| Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions. | Bsibsi M et al. | — | 2013 | → |
| Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. | International Multiple Sclerosis Genetics Consortium (IMSGC) et al. | — | 2013 | → |
| Antidepressant effects of TNF-α blockade in an animal model of depression. | Krügel U et al. | — | 2013 | → |
| Associations of CD6, TNFRSF1A and IRF8 polymorphisms with risk of inflammatory demyelinating diseases. | Park TJ et al. | — | 2013 | → |
| Autoantibody repertoires, natural biomarkers, and system controllers. | Cohen IR | — | 2013 | → |
| Clinical implications of shared genetics and pathogenesis in autoimmune diseases. | Zhernakova A et al. | — | 2013 | → |
| Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. | Ottoboni L et al. | — | 2013 | → |
| Clinical targeting of the TNF and TNFR superfamilies. | Croft M et al. | — | 2013 | → |
| Decoding multiple sclerosis: an update on genomics and future directions. | Oksenberg JR | — | 2013 | → |
| Estimation and partition of heritability in human populations using whole-genome analysis methods. | Vinkhuyzen AA et al. | — | 2013 | → |
| Genetic burden in multiple sclerosis families. | Isobe N et al. | — | 2013 | → |
| Genetic insights into common pathways and complex relationships among immune-mediated diseases. | Parkes M et al. | — | 2013 | → |
| Genetics of complex diseases: knowing gene polymorphisms do matter. | Moraes MO et al. | — | 2013 | → |
| Genomic modulators of the immune response. | Knight JC | — | 2013 | → |
| Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. | International Genetics of Ankylosing Spondylitis Consortium (IGAS) et al. | — | 2013 | → |
| IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. | Jäger J et al. | — | 2013 | → |
| Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. | Steinman L | — | 2013 | → |
| iRHOM2 takes control of rheumatoid arthritis. | Lichtenthaler SF | — | 2013 | → |
| LIGHT (TNFSF14/CD258) is a decisive factor for recovery from experimental autoimmune encephalomyelitis. | Maña P et al. | — | 2013 | → |
| Mapping of immune-mediated disease genes. | Ricaño-Ponce I et al. | — | 2013 | → |
| Metalloproteinases and their natural inhibitors in inflammation and immunity. | Khokha R et al. | — | 2013 | → |
| Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS. | Methner A et al. | — | 2013 | → |
| Multiple sclerosis: Prospects and promise. | Hauser SL et al. | — | 2013 | → |
| Neurons as targets for T cells in the nervous system. | Liblau RS et al. | — | 2013 | → |
| Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology. | Mc Guire C et al. | — | 2013 | → |
| Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis. | Yang G et al. | — | 2013 | → |
| Pleiotropy in complex traits: challenges and strategies. | Solovieff N et al. | — | 2013 | → |
| Predictive methods in drug repurposing: gold mine or just a bigger haystack? | Cavalla D | — | 2013 | → |
| Protein therapeutics targeted at the TNF superfamily. | Ware CF | — | 2013 | → |
| Recent progress in omics-driven analysis of MS to unravel pathological mechanisms. | Malekzadeh A et al. | — | 2013 | → |
| Systems approaches to human autoimmune diseases. | Banchereau R et al. | — | 2013 | → |
| The genetics of multiple sclerosis: review of current and emerging candidates. | Muñoz-Culla M et al. | — | 2013 | → |
| The mood-immunity relationship in multiple sclerosis. | Ristori G et al. | — | 2013 | → |
| Therapies for multiple sclerosis: translational achievements and outstanding needs. | Haghikia A et al. | — | 2013 | → |
| TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine. | Faustman DL et al. | — | 2013 | → |
| TNFRSF1A polymorphisms and MS: statistical signals transform into pathogenetic mechanisms. | Weinshenker B et al. | — | 2013 | → |
| TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. | Comabella M et al. | — | 2013 | → |
| Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis. | Atan D et al. | — | 2013 | → |
| Weighing in on autoimmune disease: Big data tip the scale. | Dendrou CA et al. | — | 2013 | → |
| What is the point of large-scale collections of human induced pluripotent stem cells? | McKernan R et al. | — | 2013 | → |
| An integrated map of genetic variation from 1,092 human genomes. | 1000 Genomes Project Consortium et al. | — | 2012 | → |
| From genes to characteristics of multiple sclerosis. | Harbo HF et al. | — | 2012 | → |
| Genomewide association studies and common disease--realizing clinical utility. | Fugger L et al. | — | 2012 | → |
| Multiple sclerosis: TNF receptor 1 gene variant could explain failure of TNF-blocking drugs in multiple sclerosis. | Wood H | — | 2012 | → |
| Personalized medicine in multiple sclerosis: hope or reality? | Derfuss T | — | 2012 | → |
| Progress in multiple sclerosis genetics. | Goris A et al. | — | 2012 | → |
| The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. | Goodin DS | — | 2012 | → |
| TNFα in synaptic function: switching gears. | Santello M et al. | — | 2012 | → |